3 active not recruiting, 1 completed. 2 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 2 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Vaginal Squamous Cell Carcinoma, Not Otherwise Specified: new trials by email Literature Review of Vaginal Squamous Cell Carcinoma, Not Otherwise Specified trials Research Report on Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers Durvalumab, Laboratory Biomarker Analysis, Stereotactic Radiosurgery - Advanced Cervical Adenocarcinoma, Advanced Vaginal Carcinoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 20 | 2018-07-18 | 2023-09-13 |
| Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors Atezolizumab, Bevacizumab, Laboratory Biomarker Analysis - Appendix Adenocarcinoma, Human Papillomavirus-Related Anal Squamous Cell Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 133 | 2017-03-03 | 2026-09-14 |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Biospecimen Collection, Computed Tomography, Echocardiography Test - Acinar Cell Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 798 | 2017-01-30 | 2026-06-17 |
| Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers Brachytherapy, Cisplatin, External Beam Radiation Therapy - Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 450 | 2016-05-10 | 2026-10-22 |
Adenocarcinoma, Mucinous (2) · Nasopharyngeal Carcinoma (2) · Uterine Cervical Neoplasms (2) · Vaginal Neoplasms (2) · Vulvar Neoplasms (2) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Adenoma, Islet Cell (1) · Adrenocortical Carcinoma (1) · Bile Duct Neoplasms (1) · Carcinoma, Acinar Cell (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Basal Cell (1) · Carcinoma, Endometrioid (1) · Carcinoma, Giant Cell (1) · Carcinoma, Merkel Cell (1)
Neoplasms (4) · Neoplasms by Site (4) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genital Diseases (3) · Genital Diseases, Female (3) · Genital Neoplasms, Female (3) · Urogenital Diseases (3) · Urogenital Neoplasms (3) · Uterine Neoplasms (3) · Adenocarcinoma (2) · Carcinoma (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Endocrine Gland Neoplasms (2)
Disulfides (2) · Immunoglobulin G (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (1) · Bevacizumab (1) · Brachytherapy (1) · CTLA-4 Antigen (1) · Cisplatin (1) · Congresses as Topic (1) · Ipilimumab (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1) · Platinum (1) · Radiation (1) · Radiosurgery (1)
M.D. Anderson Cancer Center (2) · National Cancer Institute (NCI) (2)
United States (4) · Canada (1) · Guam (1) · Puerto Rico (1)
Charles A Leath (1) · Kanwal P Raghav, MD (1) · Lilie L Lin (1) · Sandip P Patel (1)
PMID 29868473, PMID 31681600, PMID 31969335, PMID 33362722, PMID 33882143, PMID 34380663, PMID 34716198, PMID 35389428, PMID 38243705, PMID 38358334, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39856213, PMID 40402690, PMID 40588371, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42499790
U10CA180868 (1), U10CA180888 (1)